NASDAQ · VIR
Vir Biotechnology, Inc.
$11.75-$0.18 (-1.51%)
Vir Biotechnology, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.61% below the high.
Loading market information…
NASDAQ · ALT · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Altimmune, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.77% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Altimmune, Inc.’s forward annual dividend is $10,476.00 per share, paid monthly. The forward yield is 489,532.71% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Altimmune, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.14. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Altimmune, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 13, 2025 | -$0.26+25.71% vs estimate | $5.00K+792.86% vs estimate |
|---|
| Q4 2024 | Feb 27, 2025 | -$0.33+2.94% vs estimate | $5.00K+400.0% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | -$0.32+11.11% vs estimate | $5.00K+600.28% vs estimate |
|---|
THE ANALYST VIEW
15 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $10.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$11.75-$0.18 (-1.51%)
Vir Biotechnology, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.61% below the high.
$21.94+$0.46 (+2.14%)
Structure Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.88% below the high.
$4.28-$0.04 (-0.93%)
Arbutus Biopharma Corp’s quoted price sits in the lower half of its reported 52-week range, 21.47% below the high.
$20.86+$0.29 (+1.41%)
Assembly Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.47% below the high.
$3.34+$0.01 (+0.3%)
Indaptus Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.96% below the high.
$11.15-$0.40 (-3.46%)
Enanta Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.99% below the high.
$3.73+$0.02 (+0.54%)
Inventiva S.A.’s quoted price sits in the lower half of its reported 52-week range, 48.83% below the high.
$0.62-$0.02 (-3.84%)
Biomea Fusion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.2% below the high.
